OncoCyte Corp Cash Flow Conversion Efficiency
OncoCyte Corp cash flow conversion efficiency. Based on the latest financial reports, OncoCyte Corp (OCX) has a cash flow conversion efficiency ratio of -0.573x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.86 Million) by net assets ($10.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of OncoCyte Corp (2013–2024)
Cash flow conversion efficiency of OncoCyte Corp from 2013 to 2024. This chart illustrates how OncoCyte Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View OncoCyte Corp (OCX) share price today for real-time trading data and today's change.
OncoCyte Corp Cash Flow Conversion Ratio Explained
OncoCyte Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
OncoCyte Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OncoCyte Corp ranked by their cash flow conversion efficiency. Also see market value of OncoCyte Corp for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Apex Biotechnology Corp
TW:1733
|
0.003x |
|
Likhitha Infrastructure Limited
NSE:LIKHITHA
|
-0.026x |
|
Tae Kyung Ind
KO:015890
|
0.011x |
|
Hongli Group Inc. Ordinary Shares
NASDAQ:HLP
|
0.020x |
|
Micropolis Holding Company
NYSE MKT:MCRP
|
0.063x |
|
Kumho Petro Chemical Co Ltd
KO:011785
|
0.001x |
|
Barington/Hilco Acquisition
NASDAQ:BHAC
|
-0.004x |
|
Cameo Communications Inc
TW:6142
|
-0.032x |
Annual Cash Flow Conversion Efficiency for OncoCyte Corp (2013–2024)
The table below shows the annual cash flow conversion efficiency of OncoCyte Corp from 2013 to 2024. Review free cash flow generation of OncoCyte Corp to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-12.27 Million | $-20.71 Million | 1.688x | +285.17% |
| 2023-12-31 | $25.59 Million | $-23.32 Million | -0.911x | +31.42% |
| 2022-12-31 | $34.29 Million | $-45.57 Million | -1.329x | -141.12% |
| 2021-12-31 | $65.22 Million | $-35.94 Million | -0.551x | +28.97% |
| 2020-12-31 | $33.48 Million | $-25.98 Million | -0.776x | -21.37% |
| 2019-12-31 | $30.84 Million | $-19.71 Million | -0.639x | +81.21% |
| 2018-12-31 | $3.42 Million | $-11.65 Million | -3.403x | -11.95% |
| 2017-12-31 | $4.40 Million | $-13.38 Million | -3.040x | -298.57% |
| 2016-12-31 | $9.86 Million | $-7.52 Million | -0.763x | -87.88% |
| 2015-12-31 | $10.42 Million | $-4.23 Million | -0.406x | -137.46% |
| 2014-12-31 | $-1.07 Million | $-1.16 Million | 1.084x | +651.82% |
| 2013-12-31 | $3.62 Million | $-710.00K | -0.196x | -- |
About OncoCyte Corp
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test tha… Read more